Home -> Funding

Funding


PYTHAGORAS II (4.2.1.ε1)

'Evaluation of Immune Responses Against Highly Expressed Tumor Antigens in Lung Adenocarcinoma'
Co-funded by the European Union-European Social Fund 75%) & National Resources-EPEAK II (25%). Approved Jan 2005.


 
IRTALUNG (021795)
'Evaluation of Immune Responses Against Highly Expressed Tumor Antigens in Non-Small Cell Lung Carcinoma'
Supported by a Marie Curie Incoming International Fellowship within the 6th European Community Framework Programme. Approved Nov 2005.

 
ENTEP2004 (04EP09)
'Selection of Immunostimulating Overexpressed Tumor Antigens/Epitopes in Lung Cancer Adenocarcinoma'
Co-financed by E.U.-European Social Fund (75%), the Greek Ministry of Development-GSRT (25%) & Private Sector ANTISEL. Approved Apr 2006.


 
EΠΑν (05NOV-EU-445)
'Immunoepigenetics of Adenocarcinoma: Impact on Succesful Cancer Immunotherapy'
Co-financed by E.U.-European Social Fund (70%), the Greek Ministry of Development-GSRT (30%) & Private Sector ANTISEL. Approved Jun 2006.


 
IMMUNOEPIGENETICS (046459)
'Anti-tumor CD8 Immunity Influenced by Epigenetic Alterations'
Supported by a Marie Curie International Reintegration Grant within the 6th European Community Framework Programme. Aprroved Oct 2006.


 
GRANT IN AID
'Immunology Research'
Supported by Phizer Hellas. Approved Nov 2005.


 
MATCHING FUNDS
Approved Dec 2007.


 

AMGEN HELLAS DONATION
Approved Nov 2008.